New 2-Month TB pill cocktail could replace 6-Month regimen

NCT ID NCT06905522

Recruiting now Disease control Sponsor: Shenzhen Third People's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new ultra-short treatment for both drug-sensitive and drug-resistant tuberculosis (TB). The goal is to see if a 2-3 month regimen works as well as or better than the standard 4-6 month treatment. About 610 adults with active TB will take part. The approach could simplify care, lower costs, and reduce side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY TUBERCULOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multidrug-resistant tuberculosis pulmonary tuberculosis rifampicin-resistant tuberculosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PULMONARY TUBERCULOSIS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Beijing Chest Hospital of Capital Medical University
RECRUITING

Beijing, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
Shenzhen Third People's Hospital
RECRUITING

Shenzhen, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
The Sixth People's Hospital of the Xinjiang Uygur Autonomous Region
RECRUITING

Ürümqi, China

Contact Phone: •••-•••-•••• Email: •••••@•••••